

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Cardiovascular and Renal Drugs Advisory Committee (CRDAC) Meeting***  
FDA White Oak Campus, Building 31 Conference Center, the Great Room (Rm. 1503)  
10903 New Hampshire Avenue, Silver Spring, Maryland  
December 10, 2019

**MEETING ROSTER**

---

**ACTING DESIGNATED FEDERAL OFFICER (Non-Voting)**

**Yinghua Wang, PharmD, MPH, RAC**

Division of Advisory Committee and Consultant Management  
Office of Executive Programs, CDER, FDA

**CARDIOVASCULAR AND RENAL DRUGS ADVISORY COMMITTEE MEMBERS (Voting)**

**John H. Alexander, MD, MHSc**

Professor of Medicine  
Department of Medicine, Division of Cardiology  
Duke University School of Medicine  
Durham, North Carolina

**Jacqueline D. Alikhaani, BA**

*(Consumer Representative)*  
Volunteer and Advocate  
American Heart Association  
Los Angeles, California

**Barry R. Davis, MD, PhD**

Guy S. Parcel Chair in Public Health  
Professor, Department of Biostatistics and Data  
Science  
Director, Coordinating Center for Clinical Trials  
The University of Texas School of Public Health  
Houston, Texas

**C. Michael Gibson, MD, MS**

Professor of Medicine  
Harvard Medical School  
President  
Combined non-profit Baim and PERFUSE  
Research Institutes  
Boston, Massachusetts

**Julia B. Lewis, MD**

*(Chairperson)*  
Professor of Medicine  
Division of Nephrology  
Vanderbilt Medical Center  
Nashville, Tennessee

**John M. Mandrola, MD, FACC**

Electrophysiologist  
Baptist Medical Associates  
Louisville, Kentucky

**David J. Moliterno, MD**

Professor and Chairman  
Department of Internal Medicine  
University of Kentucky Medical Center  
Lexington, Kentucky

**Milton Packer, MD**

Distinguished Scholar in Cardiovascular Medicine  
Baylor Heart and Vascular Institute  
Baylor University Medical Center  
Dallas, Texas

**Paul M. Ridker, MD MPH, FACC, FAHA**

Eugene Braunwald Professor of Medicine  
Harvard Medical School  
Director, Center for Cardiovascular Disease  
Prevention, Division of Preventative Medicine  
Brigham and Women's Hospital  
Boston, Massachusetts

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Cardiovascular and Renal Drugs Advisory Committee (AAC) Meeting***  
December 10, 2019

**MEETING ROSTER (cont.)**

---

---

**CARDIOVASCULAR AND RENAL DRUGS ADVISORY COMMITTEE MEMBER (Non-Voting)**

**David G. Soergel, MD**

*(Industry Representative)*

Global Head

Cardiovascular, Renal and Metabolism Development

Novartis Pharma

East Hanover, New Jersey

**TEMPORARY MEMBERS (Voting)**

**James Floyd, MD, MS**

Assistant Professor of Medicine and Epidemiology

Cardiovascular Health Research Unit

University of Washington

Seattle, Washington

**Nedra Hazlett, MSN, CRNP**

*(Patient Representative)*

Women's Health Nurse Practitioner

Administrator, Atrial Fibrillation Support Forum

Murrysville, Pennsylvania

**Jenna M. Merandi, PharmD, MS, CPPS**

Medication Safety Officer

Nationwide Children's Hospital

Columbus, Ohio

**Matthew Needleman, MD, FACC, FHRS**

Commander, Medical Corps, U.S. Navy

Program Director, Cardiovascular Diseases

Fellowship, National Capital Consortium

Director, Arrhythmia Services

Walter Reed National Military Medical Center

Associate Professor of Medicine and Pediatrics

Uniformed Services University of Health Sciences

Bethesda, Maryland

**FDA PARTICIPANTS (Non-Voting)**

**Ellis F. Unger, MD**

Director

Office of Drug Evaluation I (ODE I)

Office of New Drugs (OND), CDER, FDA

**Norman Stockbridge, MD, PhD**

Director

Division of Cardiovascular and Renal Products

(DCaRP), ODE I, OND, CDER, FDA